In the last trading session, 2.41 million shares of the Humacyte Inc (NASDAQ:HUMA) were traded, and its beta was 1.38. Most recently the company’s share price was $3.20, and it changed around $0.14 or 4.75% from the last close, which brings the market valuation of the company to $411.74M. HUMA currently trades at a discount to its 52-week high of $9.97, offering almost -211.56% off that amount. The share price’s 52-week low was $2.81, which indicates that the current value has risen by an impressive 12.19% since then.
Humacyte Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended HUMA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Humacyte Inc is expected to report earnings per share of -0.25 for the current quarter.
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA has showed a green trend with a performance of 4.75% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.94 on recent trading dayincreased the stock’s daily price by 18.78%. The company’s shares are currently down -36.63% year-to-date, but still up 5.26% over the last five days. On the other hand, Humacyte Inc (NASDAQ:HUMA) is -30.13% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 60.0% from its current value. Analyst projections state that HUMA is forecast to be at a low of $6 and a high of $10.
4 analysts expect Humacyte Inc to make 800.25k in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Humacyte Inc earnings are expected to increase by -26.64% in 2025, but the outlook is positive 41.70% per year for the next five years.
HUMA Dividends
Humacyte Inc’s next quarterly earnings report is expected to be released in April.
VANGUARD GROUP INC, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.63 shares worth $8.42 million, making up 2.09% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.59 shares worth around $8.3 million, which represents about 2.06% of the total shares outstanding.
